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Introduction.Acuteheartfailure(AHF)isassociatedwithahigherriskfortheoccurrenceofrehospitalizationanddeath.Galectin-3
(GAL3)iselevatedinAHFpatientsandisanindicatorinpredictingshort-termmortality.Thetotalbodywaterusingbioimpedance
vector analysis (BIVA) is able to identify mortality within AHF patients. The aim of this study was to evaluate the short- and long-
term predictive value of GAL3, BIVA, and the combination of both in AHF patients in Emergency Department (ED). Methods.20 5
ED patients with AHF were evaluated by testing for B type natriuretic peptide (BNP) and GAL3. The primary endpoint was death
and rehospitalization at 30, 60, 90, and 180 days and 12 and 18 months. AHF patients were evaluated at the moment of ED arrival
with clinical judgment and GAL3 and BIVA measurement. Results. GAL3 level was significantly higher in patients >71 years old,
and with eGFR < 30cc/min. The area under the curve (AUC) of GAL3 + BIVA, GAL3 and BIVA for death and rehospitalization
both when considered in total and when considered serially for the follow-up period showed that the combination has a better
prognostic value. Kaplan-Meier survival curve for GAL3 values >17.8ng/mL shows significant survival difference. At multivariate
CoxregressionanalysisGAL3isanindependentvariabletopredict death + rehospitalization with a value of 32.24ng/mL at 30 days
(𝑃 < 0.005). Conclusion. In patients admitted for AHF an early assessment of GAL3 and BIVA seems to be useful in identifying
patients at high risk for death and rehospitalization at short and long term. Combining the biomarker and the device could be of
great utility since they monitor the severity of two pathophysiological different mechanisms: heart fibrosis and fluid overload.
1. Introduction
In patients with acute heart failure (AHF), the occurrence
of rehospitalization and death is very common [1, 2]. There
is need for tools to immediately identify patients with AHF
at high risk for short- and long-term mortality and read-
mission. Galectin-3 (GAL3) is a 𝗽-galactoside-binding lectin
overexpressed by macrophages during phagocytosis that has
bee ns h o w nt obee l ev a t edi npa ti e n t sw i thA H Fr e p r e se n ti n g
a prognostic biomarker for future adverse events such as
death and rehospitalization [3, 4]. The adverse outcome in
patients with elevated circulating level of GAL3 has been
linkedwiththepresenceofenhancedamountofthefibrosisof
theheart[5].Betweenpatientsthatneedtobehospitalizedfor
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AHFtheoccurrenceofbodycongestionisacommonfinding
[6].
Recently, the assessment of total body water using
bioimpedance vector analysis (BIVA) has been suggested to
beusefulforthedifferentialdiagnosisofdyspnea,identifying
patients with fluid overload [7]. Moreover, within subjects
referringto the Emergency Department(ED) for AHF, BIVA
has been demonstrated to be able to identify people at high
risk for short-term mortality [8, 9]. In consideration of the
two different aspects of GAL3 and of BIVA (the first is a
fibrosis marker, and the second is a dynamic marker of
congestion), we decided to evaluate in this study the degree
of congestion correlated to that of fibrosis in AHF patients
a l o n eo rt o g e t h e rf o rt h ep r e d i c t i o no fe v e n t s .S of a rn od a t a
are available on potential usefulness of combining GAL3,
as a biomarker of heart fibrosis, and BIVA, as a device for
detecting fluid overload in patients with AHF in order to
i d e n t i f ys u b j e c ta th i g hr i s kf o rf u t u r ea d v e r s eo u t c o m e .Th e
a i mo ft h i ss t u d yw a st oe v a l u a t et h es h o r t -a n dl o n g - t e r m
predictive value of GAL3, BIVA, and the combination of
both in patients with AHF at the moment of their hospital
admission.
2. Materials and Methods
2.1. Study Design. In a prospective, blinded international
study, patients presenting to ED with AHF were evaluated by
testing for B type natriuretic peptide (BNP) and GAL3. The
primary endpoint was death and rehospitalization at 30, 60,
90, and 180 days and 12 and 18 months.
We enrolled 205 subjects from March 2012 to September
2013 at two tertiary care academic medical centers members
of the Global Research on Acute Conditions Team (GREAT):
Sant’Andrea Hospital (Rome, Italy) and the Massachusetts
General Hospital (Boston, MA). All study procedures were
approved by local institutional review boards. AHF patients
were evaluated at the moment of ED arrival with clinical
judgement and blood routine laboratory tests plus GAL3
and BIVA. Inclusion criteria included moderate or severely
symptomatic AHF (classified on the basis of current guide-
lines [10]) requiring intensification of diuretic therapy [10].
Exclusion criteria included renal failure requiring current
renal replacement therapy, ≥8 hours from the first dose
of intravenous diuretic, and unwillingness or inability to
participateinstudyprocedures.AtthemomentofEDarrival,
baseline demographics, vital signs, and results of physical
examination were evaluated and recorded after informed
consent was signed. The protocol was designed following
t h ec r i t e r i ao ft h eD e c l a r a t i o no fH e l s i n k ia n dw a sa p p r o v e d
by the ethical committee of each participating hospital.
Peripheral venous blood was withdrawn and processed as
noted below.
2.2. Blood Analysis. Peripheral venous blood was withdrawn
by each patient and put into tubes containing ethylenedi-
aminetetraacetic acid or no anticoagulant and spun for 15
minutes;sampleswereimmediatelyaliquotedtofreezertubes
andfrozenat−80
∘ forbiomarkersmeasurementfollowingthe
completionofthetrial.Sampleswerethawedforthefirsttime
for measurement of biomarkers. Biomarkers of myocardial
stretch BNP (Alere Triage BNP, San Diego, CA), biomarkers
of risk stratification of patients GAL3 (VIDAS, Biomerieux,
Marcy l’´ Etoile, France), and biomarkers of renal function
included blood urea nitrogen (BUN), serum creatinine, and
estimated glomerular filtration rate (eGFR, estimated using
the simplified modification of diet in renal disease equation
[11]). Clinicians were blinded to GAL3 and BIVA results.
2.3. Galectin-3. GAL3 (VIDAS, Biomerieux, Marcy l’´ Etoile,
France) is a quantitative, one-step sandwich assay with
fluorescence detection, designed for use with the VIDAS
automatedimmunoassaysystem.Brieflythesystemmeasures
GAL3 in human serum or plasma (200𝜇L) using the ELFA
(enzyme-linked fluorescent assay) technique in 20 minutes.
A l ls t a g e so ft h ea s s a ya r ep e r f o r m e da u t o m a t i c a l l yb yt h e
instrument, calculating the concentration of GAL3 relative
to a stored calibration curve and enabling patients to be
assigned as low, intermediate, or high risk of GAL3 mediated
HF. Correct assay performance and validation of results are
ensured by analysis of the control sample included in the
kit. Decisional cut-offs are represented by ≤17.8ng/mL “low
risk,” 17.8–25.9ng/mL “intermediate risk,” and ≥25.9ng/mL
“highrisk”[12];thethreeriskcategorieshavebeenpreviously
defined for the BGM Galectin-3 microplate assay [13].
2.4. BIVA Assessment. We used standard tetrapolar bioelec-
trical impedance electrodes at a frequency of 50kHz (Akern
Srl, Pontassieve, Florence, Italy). The BIVA measurement
assessed at patients’ ED arrival was performed at bedside,
with the patient supine, without metal contacts, and with
inferior limbs at 45
∘ and superior limbs abducted at 30
∘ to
a v o i ds k i nc o n t a c t s .F o u rs k i ne l e c t r o d e sw e r ea p p l i e d( t w o
on the wrist and two on the ipsilateral ankle) maintaining
a minimal interelectrode distance of 5cm. The machine
used an alternating current flux of 300𝜇Aa n da no p e r a t i n g
frequency of 50kHz. The results were visualized in two
ways: as a vector or as a BIVA-derived hydration percentage.
The first method includes a direct impedance plot which
measures resistance (Rz) and reactance (Xc) as a bivariate
vector in a nomogram. Reference values adjusted for age,
BMI, and gender are plotted as tolerance ellipses in the same
coordinatesystem. Three tolerance ellipses are distinguished,
corresponding to the 50th, 75th, and 95th vector percentiles
of the healthy reference population. The major axis of this
ellipse indexes hydration status and the minor axis reflects
tissue mass. The second method involves a scale called a
hydrograph (or hydrogram), which expresses the state of
hydration as a percentage (HI). This value is calculated by
an independently determined equation that uses the two
components of BIVA, Rz and Xc. The normal value is 73.3%
with tolerance between 72.7% and 74.3%, corresponding to
the 50th percentile. On arrival at the ED, Rz and Xc were
recorded, normalized by the subject’s height, and graphically
expressed on the Rz-Xc plane; furthermore, HI was also
assessed [8, 14–17]. Clinicians were blinded to the results of
BIVA.BioMed Research International 3
In-hospital death = 20
Death 30 days = 10
Death 60 days = 4
Death 90 days = 3
Death 180 days = 5
Death 1 year = 3
Death 18 months = 2
Total n 47 (24.2%)
Rehospitalization 30 days = 30 
Rehospitalization 60 days = 7
Rehospitalization 90 days = 8
Rehospitalization 180 days = 13
Rehospitalization 1 year = 5
Rehospitalization 18 months = 4
Total n 67 (34.5%)
Events
Statistical analysis 
Total enrolled patients (n = 205)
Patients excluded:
 (n = 194)
Rome =1 5 4pts
Boston =5 0pts
missing data (n=1 1 )
group
Figure 1: Flowchart of the study.
2.5.Follow-Up. In-hospital,30-,60-,90-,and180-dayand12-
and 18-month follow-up events (deaths or rehospitalization)
were recorded.
2.6. Statistical Analysis. Continuous variables were sum-
marized as mean ± standard deviation (SD) if normally
distributed and as median and interquartile range [IQR]
if not normally distributed. Discrete variables are shown
as percentage. Baseline variables of study participants for
events (death + rehospitalization) and death were compared
using Student’s 𝑡-test for continuous variables or 𝑋2 test
for discrete variables if data were normally distributed; the
Mann-Whitney 𝑈 test was used for continuous variables
and Fisher’s exact test for discrete variables in the states of
nonnormality. To determine the prognostic value of GAL3
and phase angle, the receiver operating characteristic (ROC)
tests compared the results of GAL3 and phase angle and
combinationofbothforpredictingrehospitalizationordeath,
expressed as area under the curve (AUC); the 𝑃 value was
obtained. Univariable comparisons between baseline charac-
teristics were used to identify candidate variables for entry
to a multivariable logistic regression model in order to select
the variables most predictive of patients’ outcomes; only
those with a 𝑃 value <0.05 were retained for multivariable
modeling. Net reclassification index (NRI) analysis was used
to improve the accuracy of the risk-prediction model for
in-hospital mortality. All statistical analyses were performed
using Medcalc version 12.1.4 (Medcalc Software, Mariakerke,
Belgium)software. All 𝑃 values are two-sided with a value of
<0.05 considered significant.
3. Results
Figure 1 showed the flowchart of the study, 11 patients were
excluded formissingdata,totaldeathsinhospitalandduring
18-month follow-up were 47 (24.2%), and total rehospital-
ization during all follow-up period was 67 (34.5%). Patients’
characteristics are showed in Table 1. At the moment of
ED arrival compared to survivors there were no statistically
significant differences for demographic data in patients with
death or total adverse events (rehospitalization and death)
observed in all periods of the study. Beta blockers use
was higher in patients who survived. On the contrary, in
patients who died, there was a significant increase of serum
creatinine(sCr),bloodureanitrogen(BUN),andwhiteblood
cells (WBC). When considering the combination of death
and rehospitalization during follow-up period, there was
significant increase of age, hypertension, diabetes mellitus,
use of ACE inhibitors (ACEi), sCr, and BUN values in
patientswhodevelopevents.Table 2 showsthat,comparedto
survivors, GAL3 level at admission was significantly higher
in both groups that died or that developed death + rehos-
pitalization during follow-up. On the contrary, BNP value
was not different within groups of patients who survived,
died, or were rehospitalized. As for BIVA data, there was a
significant increase of Xc in patients who died during follow-
up compared to survivors (Table 2). Figure 2 shows the value
of GAL3 subdivided in quartileson the basisof age (a) and of
eGFR (b). Figure 2(a) demonstrates that GAL3 level was sig-
nificantly higher in patients within quartiles of age >71 years
and in patients within quartiles of eGFR<30mL/min/1.73m
2
(Figure 2(b)).Table 3 showstheROCcurveanalysisofGAL3,4 BioMed Research International
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Figure 2: GAL3 levels increase proportionally with age quartiles (a) and decrease with eGFR quartiles (b).
Table 2: Baseline biomarkers as a function of the primary endpoint of events (in-hospital death and rehospitalization and death at 18-month
follow-up) and death.
Variable (mean ± SD) Total
(𝑁 = 194)
Events (death + rehospitalization) 𝑃 Death 𝑃
Yes (𝑁=8 8 )N o ( 𝑁 = 106)Y e s ( 𝑁=4 7 )N o ( 𝑁 = 147)
GAL3 (ng/mL) 32.19 ± 19.03 37.15 ± 21.8 26.12 ± 13.6 <0.001 40.58 ± 23.09 28.16 ± 15.96 <0.001
BNP (pg/mL) 872.9 ± 1024.4 969.5 ± 1205.5 774.5 ± 837.1 0.91 1030.0 ± 1059.9 821.25 ± 1014.6 0.27
Hydration (%) 79.44 ± 6.55 80.75 ± 6.55 78.75 ± 6.66 0.75 80.62 ± 7.6 79.05 ± 6.19 0.11
Xc/H 34.8 ± 16.4 27.0 ± 14.2 27.35 ± 11.63 0.93 28.25 ± 26.85 17.07 ± 11.28 0.05
Rz/H 364.25 ± 136.8 363.73 ± 140.02 341.07 ± 120.88 0.21 386.05 ± 340.54 155.30 ± 119.68 0.28
Phase angle 4.4 ± 1.7 4.3 ± 1.7 4.7 ± 1.5 0.17 4.24 ± 2.09 4.62 ± 1.48 0.79
BIVA (phase angle), and GAL3 + phase angle for mortality
andrehospitalizationfor30,60,90,and180daysand12and18
months. Figure 3 shows the Kaplan-Meier survival curve for
death (a) and for total events (death and rehospitalization)
(b) on the basis of GAL3 values greater than 17.8ng/mL,
international cut-off [12]. It is evident that in patients with
GAL3 >17.8ng/mL there was a higher incidence of death
or of all events (death and rehospitalization) during 18-
month follow-up. Cox regression analysis demonstrated that
GAL3 is an indipendent variable to predict death to predict
death and rehospitalization with a value of 32.24ng/mL at
30 days (𝑃 < 0.005). We constructed a clinical model based
on variables suggested by the referee (age, sex, BNP, LVEF,
and creatinine), using as decisional cut-off of the median
values of our entire population. Each patient was classified
at low or high risk for development of events on the basis
of the positivity at the different predictive variables. The best
predictive model in terms of sensitivity and specificity was
obtained with positivity at 3 out of 5 variables (sensitivity
61.4%, specificity 61.8%, and accuracy 62%). The use of
galectin-3 at a threshold of 17.8 combined to previously
described clinical model was able to improve the global risk
classification (NRI) of 18% (NRI for events +27%, NRI for
no events −9%, 𝑃 = 0.021). The use of galectin-3 and
BIVA was able to get a NRI of 20% especially improving the
“noevents”correctreclassification(NRIforevents+16%,NRI
for no events +4%, 𝑃 = 0.012).
4. Discussion
Cardiac remodeling and congestion are crucial determinants
of the clinical outcome of heart failure (HF) and are linked
to disease progression and poor prognosis [18]. Recently
it has been demonstrated that slowing or reversing the
progressionofremodelingcouldbecomeatherapeuticgoalof
HFpatients’management.Circulatingplasmaconcentrations
of BNP is currently the most commonly used biomarker in
AHF and its level is generally increased in proportion to the
severity of the myocardial stretch or overload [19]. However,
theapplicabilityofBNPislimited,sinceitslevelssubstantially
vary over the day, and is not related to the underlying
cardiac disease process. Prognostic value of GAL3 when
upregulated in hypertrophied hearts has been confirmed in
a number of studies [2, 3, 20–25]. Data from our study
strongly support the original research papers that showed
how GAL3 could play an important role in the underlying
structural heart disease processes. Elevated value of GAL3
is associated with heart failure progression due to increase
of heart fibrosis leading to poor outcome in AHF patients.BioMed Research International 7
Table 3: ROC curve analysis of GAL3, BIVA (phase angle), and GAL3 + phase angle for mortality and rehospitalization for 30, 60, and 90
d a y s ,1y e a r ,a n d1 8m o n t h s .
GAL3 + phase angle GAL3 Phase angle
AUC 𝑃 AUC 𝑃 AUC 𝑃
Rehospitalization
30 days 0.526 ns 0.51 ns 0.52 ns
60 days 0.625 0.003 0.61 0.04 0.54 0.04
90 days 0.583 ns 0.57 ns 0.57 ns
180 days 0.545 0.05 0.54 ns 0.52 ns
12 months 0.52 ns 0.54 ns 0.53 ns
18 months 0.620 0.04 0.59 0.04 0.52 ns
Death
30 days 0.764 0.0001 0.69 0.002 0.64 0.01
60 days 0.754 0.0001 0.68 0.0001 0.68 0.003
90 days 0.667 0.005 0.64 0.01 0.58 0.04
180 days 0.841 0.0001 0.67 0.006 0.79 0.0001
12 months 0.833 0.0001 0.72 0.002 0.79 0.0001
18 months 0.863 0.0001 0.73 0.0003 0.86 0.0001
Table 4: Multivariate Cox regression analysis GAL3 is an independent variable to predict death and rehospitalization with a value of
32.24ng/mL at 30 days (𝑃 < 0.005).
Variables Logistic regression
𝐵 SE Wald 𝑃
GAL3 0.671 0.370 3.290 0.05
Phase angle −1.462 0.773 3.574 <0.03
Hi 0.103 0.708 0.021 ns
From our results GAL3 value in patients who develop higher
incidence of death and rehospitalization was independent
risk factor with a cut-off of 32.24ng/mL greater than the cut-
off of 17.8ng/mL that is currently accepted, Table 4 [12, 20–
26]. Moreover GAL3 was statistically higher in patients who
died (𝑃 < 0.001) and were rehospitalized compared to
survivors (𝑃 < 0.001) .O u rr e s u l t sa r ea l s oi na g r e e m e n t
with van Kimmenade et al. who demonstrated that, elevated
GAL3 levels in patients presenting to ED for AHF, GAL3
was the best independent predictor for 60-day mortality [4].
Furthermore our results are in the same directions with the
ones from Shah et al. who demonstrated that in patients
with AHF presenting to ED a value of GAL3 levels above
the median value had higher incidence of mortality [3]. Our
study is probably the first in which a long-term follow-up
for mortality and rehospitalization has been studied in AHF
patients in consideration of GAL3 levels measured in ED;
furthermore,ourfollow-upstudywasseriallyconducted(30-
,60-,90-,and180-dayand12-and18-monthfollow-upevents
(deaths or rehospitalization)). In literature there are very few
data on short- and long-term follow-up but all these papers
are not serially [3, 4, 27]. Recently published data from three
large research trials from HF patients. They demonstrated
that elevation of GAL3 levels was significantly predictive of
rehospitalization of 30 days from discharge. Moreover those
patients of elevation of GAL3 at the time of hospitalization
were readmitted within 30 days at three times of rate of
patients without GAL3 elevation and the increased risk of
hospitalization conferred by GAL3 elevation persisted at 60,
90, and 120 days in the study [28].
As described in literature GAL3 was able to identify
those AHF patients at risk for short-term death or for the
combinationofdeathandreadmission[4];inourstudyGAL3
m e a s u r e da tt h em o m e n to fE Da r r i v a l sp r e d i c t sa d v e r s e
events better than BNP. So we can consider that on the
b a s i so ft h i sd a t aB N Ph a sn o tar e a lp r o g n o s t i cv a l u ea t
admission; our group already demonstrated this finding in
the ITALIAN RED study [29]. However, we must underline
the fact that BNP is internationally considered as the gold
standard biomarker in any risk score of AHF patients.
WealsoanalyzedthelevelsofGAL3basedoneGFRquar-
tilesandwedemonstratedthatGAL3levelsweresignificantly
higherinpatientswithreducedeGFR(<30mL/min/1.73m
2).
O’Seaghdha et al. already demonstrated that high levels of
GAL3 were associated with a rapid decline of eGFR and with
a higher risk of incidence of chronic kidney disease (CKD)
[30]. Findings from our study are also supported by a study
from Tang et al. who recently demonstrated that high GAL3
levels are associated with a poor renal function [24]. As a
consequence, the inverse relationship between GAL3 and
renalfunction,whichweobservedinourAHFpatients,leads
t ot h es u g g e s t i o nt h a ti n c r e a s e dp l a s m aG A L 3i nA H Fm i g h t
be linked to renal dysfunction, and the ability of GAL3 to
p r e d i c to u t c o m e si nH Fm i g h tr e fl e c tt h ec o n s e q u e n c e so f
renal impairment [3, 24, 25]. Moreover, GAL3 levels were
significantly higher in patients with age >71 years, too. This8 BioMed Research International
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Figure 3: Kaplan-Meier for death (a) and events (b) on the basis of GAL3 values greater than 17.8ng/mL.
suggests that in evaluating the value of GAL3 the physician
should take into account the age of patients as confounding
factor.ThisassociationofelevatedGAL3levelandageshould
not be surprising; it is well known that heart fibrosis is a
structural process related to aging. Other authors already
foundthisrelationshipwithGAL3andageinthesamecohort
of patients [24]. We also found that BIVA had significant
prognostic value for death for each considered follow-up
time. This is not surprising and confirms previous study of
our group, we also demonstrated additive value for AHF risk
stratification of BIVA + BNP [8, 9]. The most important of
our opinion results of our study is that the combination of
BIVA + GAL3 increases the prognostic value for death and
also for rehospitalization. It seems that the prognostic value
of the combining of BIVA and GAL3 is of great significance
since they mirror two different physiopathological aspects
of HF. BIVA (phase angle) represents the degree of body
fluid congestion, typical of AHF patients especially in the
end stage of the disease; on the other hand, GAL3 value
represents the level of fibrosis and the heart remodeling [31].
The combination of BIVA (phase angle) and GAL3 seems
to have the better AUC compared to BIVA alone or GAL3
alone in predicting patients’ adverse outcome. Nevertheless
in our study multivariate Cox regression analysis showed
that GAL3 is an independent variable more than BIVA
variables to predict death and rehospitalization of value
32.24ng/mL only at 30 days. These results strengthen the
hypothesisthatGAL3couldbeconsideredabetterpredictive
marker in comparison to BIVA and BNP when measured at
admission in ED. More studies on larger population group
are needed to confirm this hypothesis. When the survival
Kaplan-Meier curve was made for GAL3, we found that,
considering the cut-off of 17.8ng/mL, those patients above
this cut-off had a significant higher incidence of death and
rehospitalization. This confirms the importance of cut-off of
GAL3 of 17.8ng/mL representing an additive value to help
physicians especially emergency physicians to individuate
those patients of adverse outcomes.
5. Conclusion
In patients admitted for AHF an early assessment of GAL3
and BIVA seems to be useful in identifying patients at high
risk for death and rehospitalization at short and long term.
Combining the biomarker and the device could be of great
utility since they are monitoring the severity of two patho-
physiological different mechanisms underlining the severity
of disease: heart fibrosis and fluid overload. GAL3 per se
has the strongest independent predicting value for death and
rehospitalizationat30dayswithacut-offof32.24ng/mL.The
useofcombiningGAL3andBIVAassessment,atthemoment
ofAHFpatients’presentation,couldsupportdecisionmaking
and different therapeutic approach.
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